Pharmaceutical Industry News and Market Updates
McKesson transformation supports earnings growth as valuation stays below historical median
McKesson is strengthening its shift beyond low-margin drug distribution as higher-margin oncology, technology and specialty care businesses contribute a larger share of profit. The company has ...
Australia medicine shortages expose risks for critical drug supply
Australia is facing repeated shortages of critical medicines, with several life-saving drugs remaining hard to source well beyond October 2026. An ABC analysis of Therapeutic Goods Administration ...
Pharmaniaga posts sharp rise in third-quarter profit, targets launch of nine new products
Pharmaniaga Bhd's third-quarter performance was driven by a substantial tax credit and lower financing costs, as the group continued its recovery following its financial restructuring. The ...
U.S. FDA fast-track drug review program stalls after leadership departures
A drug review pilot launched in 2025 to speed approvals for treatments tied to national priorities is no longer advancing new applications at the U.S. Food and Drug Administration. The slowdown ...
Gene therapy sector seeks more durable financing model
Cell and gene therapy is delivering potentially transformative treatments for rare diseases, but its commercial model remains under pressure as investors question how reliably companies can scale ...
CANARX executives face U.S. drug importation charges
Federal prosecutors are pursuing criminal charges against two senior officials of Canadian prescription supplier CANARX over an alleged years-long scheme to bring drugs into the U.S. outside legal ...
UK seeks to use NHS data to drive AI-led pharmaceutical investment
Britain is positioning health data as a core asset in its push to expand life sciences and artificial intelligence activity. Science minister Chris McDonald says the NHS’s long-term patient ...
China drugmakers shift doctor outreach to AI apps as anti-graft crackdown disrupts marketing
China's pharmaceutical industry is redirecting doctor engagement toward medical AI apps as tighter anti-corruption enforcement makes traditional hospital visits harder and less effective. The ...
Big Caring could command a higher post-listing valuation, says BIMB Securities
Strong institutional investor demand and Big Caring Group Bhd’s position in the fragmented pharmacy market support the prospect of a premium post-listing valuation. However, the stock’s ...
Moderna sees cancer vaccine expansion as major oncology growth opportunity
Moderna is pushing beyond treatment into cancer prevention as it develops personalised mRNA vaccines for high-risk patients. The company says the approach could eventually extend from melanoma ...
Drugmakers' GLP-1 push raises insulin supply risks in poorer markets
Rising pharmaceutical investment in GLP-1 obesity and diabetes drugs is increasing concern that basic diabetes care could be sidelined in lower-income countries. A new warning highlights that ...
Hims & Hers narrows 2026 revenue outlook as margin pressure weighs on growth
Hims & Hers Health is tightening its 2026 revenue guidance as its push into branded weight-loss drugs and international markets puts pressure on gross margins. The updated range comes in below ...
Hims & Hers adds Andrew Huberman to board as telehealth group expands into personalized care
As telehealth companies push deeper into weight loss, testosterone and preventive wellness, Hims & Hers is bringing a major health-media figure into a formal governance role. Andrew Huberman says ...
U.S. FDA orders GLP-1 drugmakers to add blindness risk warning
Popular GLP-1 weight-loss medicines face a new U.S. regulatory requirement after officials identified a potential increased risk tied to a rare eye disorder. The move affects manufacturers ...
CVC and GBL clear path to delist Recordati after topping 90% stake
An investor consortium targeting Italian drugmaker Recordati has moved above the ownership threshold needed to take the company off the stock market. The holding reaches 91.9% after additional ...
Novonesis explores GLP-1 companion supplements as obesity drug boom reshapes wellness market
Rising use of GLP-1 weight-loss medicines is opening a new commercial opportunity for supplement makers targeting patients' broader health needs. Novonesis says it is studying microbiome products ...
Johnson & Johnson leads $100 million Delix funding round for depression drug development
Large drugmakers are increasing their exposure to psychedelic-inspired treatments as developers try to separate mental health benefits from hallucinogenic side effects. In that context, Johnson & ...
GSK and Moderna settle vaccine patent dispute across U.S. and Europe
The agreement closes a cross-border patent fight over mRNA vaccine technology that had added to a broader web of litigation in the sector. The settlement covers Moderna's COVID-19 shots Spikevax ...
Invesco Pharmaceuticals ETF technical strength supports further gains
Defensive pockets of the market continue to attract attention as broader equity performance weakens and fewer funds hold above key trend levels. Invesco Pharmaceuticals ETF, trading under ticker ...
Canada retail sales rise as fuel and pharmaceutical categories lead August gains
Canada's retail sector posts broad-based year-over-year growth in August, with total sales reaching $76.3 billion across most commodity classes. The increase is led by higher fuel sales amid ...
Eli Lilly expands obesity drug sales through Hims & Hers platform
Eli Lilly is broadening its direct-to-consumer obesity drug distribution by allowing Hims & Hers Health to sell Zepbound and Foundayo directly on its telehealth platform. The agreement removes a ...
